BR112019023336A2 - Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação - Google Patents

Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação Download PDF

Info

Publication number
BR112019023336A2
BR112019023336A2 BR112019023336-9A BR112019023336A BR112019023336A2 BR 112019023336 A2 BR112019023336 A2 BR 112019023336A2 BR 112019023336 A BR112019023336 A BR 112019023336A BR 112019023336 A2 BR112019023336 A2 BR 112019023336A2
Authority
BR
Brazil
Prior art keywords
therapy
useful
preparation
conjugates
peptidic
Prior art date
Application number
BR112019023336-9A
Other languages
English (en)
Inventor
Bouchard Hervé
Brun Marie-Priscille
Hubert Philippe
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112019023336A2 publication Critical patent/BR112019023336A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se aos compostos de fórmula (i): (i) em que rcg1 representa um grupo químico reativo que é reativo a um grupo químico presente em um polipeptídeo, tal como um anticorpo; p representa h, oh ou um o ativado; e l representa um ligante específico. a descrição também se refere a cargas úteis de criptoficina, bem como aos conjugados de criptoficina, a composições contendo-os e a seu uso terapêutico, especialmente como agentes anticancerígenos. a descrição também se refere ao processo para a preparação destes conjugados.
BR112019023336-9A 2017-05-10 2018-05-09 Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação BR112019023336A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305531.0 2017-05-10
EP17305531 2017-05-10
PCT/EP2018/061989 WO2018206635A1 (en) 2017-05-10 2018-05-09 Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation

Publications (1)

Publication Number Publication Date
BR112019023336A2 true BR112019023336A2 (pt) 2020-06-16

Family

ID=58873750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023336-9A BR112019023336A2 (pt) 2017-05-10 2018-05-09 Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação

Country Status (20)

Country Link
US (4) US20200093934A1 (pt)
EP (1) EP3621658A1 (pt)
JP (2) JP2020519610A (pt)
KR (1) KR20200005580A (pt)
CN (1) CN110831633A (pt)
AR (1) AR111781A1 (pt)
AU (2) AU2018265333C1 (pt)
BR (1) BR112019023336A2 (pt)
CA (1) CA3062977A1 (pt)
CO (1) CO2019012108A2 (pt)
EA (1) EA201992667A1 (pt)
EC (1) ECSP19078277A (pt)
IL (1) IL270507B2 (pt)
MA (1) MA50764A (pt)
MX (1) MX2019013421A (pt)
PH (1) PH12019550230A1 (pt)
TN (1) TN2019000303A1 (pt)
TW (1) TWI778059B (pt)
UY (1) UY37728A (pt)
WO (1) WO2018206635A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110831633A (zh) 2017-05-10 2020-02-21 赛诺菲 可用于治疗的肽类接头和念珠藻素缀合物及其制备
CN111154133B (zh) * 2020-01-03 2022-07-12 万华化学集团股份有限公司 一种环氧树脂发泡剂，环氧树脂组合物及环氧发泡材料的制备方法和用途
CN114053426B (zh) * 2020-07-30 2024-06-18 成都科岭源医药技术有限公司 一种双药链接组装单元及双药靶向接头-药物偶联物
CN115105607A (zh) * 2021-03-22 2022-09-27 成都科岭源医药技术有限公司 一种用于adc的双药-接头的制备方法及其用途
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017093A1 (en) 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins
IL128610A (en) * 1996-08-30 2004-07-25 Lilly Co Eli Cryptophycin compound and its use as a medicament for treating neoplasm
US20020128185A1 (en) 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP2044122B1 (en) 2006-07-18 2018-03-28 Sanofi Antagonist antibody against epha2 for the treatment of cancer
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
WO2011000152A1 (zh) 2009-06-30 2011-01-06 上海贝尔股份有限公司 在无线局域网中移动终端漫游的方法、相关的接入控制器和接入点设备
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
WO2015057876A1 (en) * 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
EA201690780A1 (ru) 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof
CN107249643A (zh) * 2014-12-09 2017-10-13 艾伯维公司 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
JP2018515457A (ja) * 2015-04-21 2018-06-14 アッヴィ・ステムセントルクス・エル・エル・シー カリケアマイシン構築物および使用方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
CN110831633A (zh) 2017-05-10 2020-02-21 赛诺菲 可用于治疗的肽类接头和念珠藻素缀合物及其制备

Also Published As

Publication number Publication date
KR20200005580A (ko) 2020-01-15
US20180369401A1 (en) 2018-12-27
AU2018265333A1 (en) 2019-11-28
AU2018265333B2 (en) 2022-07-21
JP2020519610A (ja) 2020-07-02
CO2019012108A2 (es) 2020-02-28
CN110831633A (zh) 2020-02-21
ECSP19078277A (es) 2019-11-30
TWI778059B (zh) 2022-09-21
IL270507B2 (en) 2023-08-01
JP2023085475A (ja) 2023-06-20
AU2022204711A1 (en) 2022-07-21
CA3062977A1 (en) 2018-11-15
MX2019013421A (es) 2020-02-05
MA50764A (fr) 2020-03-18
AR111781A1 (es) 2019-08-21
TN2019000303A1 (en) 2021-05-07
US11007275B2 (en) 2021-05-18
UY37728A (es) 2019-01-02
US20200093934A1 (en) 2020-03-26
US11998611B2 (en) 2024-06-04
EP3621658A1 (en) 2020-03-18
US20210228726A1 (en) 2021-07-29
US20200054760A1 (en) 2020-02-20
IL270507A (pt) 2019-12-31
TW201907957A (zh) 2019-03-01
AU2022204711B2 (en) 2024-01-04
WO2018206635A1 (en) 2018-11-15
AU2018265333C1 (en) 2023-08-17
EA201992667A1 (ru) 2020-03-10
PH12019550230A1 (en) 2020-07-06
IL270507B1 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
BR112019023336A2 (pt) Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação
PH12020551959A1 (en) Fxr (nr1h4) modulating compounds
MX2018015443A (es) Compuestos moduladores de fxr (nr1h4).
NZ732246A (en) Hydroxy containing fxr (nr1h4) modulating compounds
BR112018075166A2 (pt) derivados de carbonucleosídeo substituídos úteis como agentes anticâncer
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
MX2017007522A (es) Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos.
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
CL2009001065A1 (es) Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros.
BRPI1011043B8 (pt) fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica
PH12018500852A1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
CL2014001880A1 (es) Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado.
BR112014016635B8 (pt) composto, composição, e, uso de um composto
TN2017000255A1 (en) Radio-pharmaceutical complexes
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
NZ716155A (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
BR112017012022A2 (pt) complexos macromoleculares de metais de transição para o tratamento do cancro e seu processo de preparação
BR112018007673A2 (pt) ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?
BRPI0909142B8 (pt) composto cíclico e sal do mesmo, seu uso, seu processo de preparação, e composição farmacêutica
BR112016010409A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação
BR112015005560A2 (pt) derivados de macrolídeos, sua preparação e seu uso terapêutico
BR112016002724A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica e uso de composto
BR112015024571A2 (pt) compostos de complexo de ferro(iii), medicamento, e, composição
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]